REGN
NASDAQ · Biotechnology
Regeneron Pharmaceuticals
$801.82
-2.08 (-0.26%)
Financial Highlights (FY 2026)
Revenue
13.56B
Net Income
4.26B
Gross Margin
86.6%
Profit Margin
31.4%
Rev Growth
+5.6%
D/E Ratio
0.09
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 86.6% | 86.6% | 51.6% | 51.6% |
| Operating Margin | 24.9% | 22.5% | 3.0% | 2.7% |
| Profit Margin | 31.4% | 29.8% | 2.7% | 2.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 13.56B | 12.84B | 59.21B | 47.24B |
| Gross Profit | 11.74B | 11.11B | 30.53B | 24.35B |
| Operating Income | 3.38B | 2.88B | 1.80B | 1.27B |
| Net Income | 4.26B | 3.63B | 1.62B | 1.36B |
| Gross Margin | 86.6% | 86.6% | 51.6% | 51.6% |
| Operating Margin | 24.9% | 22.5% | 3.0% | 2.7% |
| Profit Margin | 31.4% | 29.8% | 2.7% | 2.9% |
| Rev Growth | +5.6% | +5.6% | +14.6% | -9.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.21B | 3.21B | 8.72B | 6.67B |
| Total Equity | 37.08B | 37.08B | 41.22B | 41.73B |
| D/E Ratio | 0.09 | 0.09 | 0.21 | 0.16 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 3.90B | 3.50B | 2.06B | 1.48B |
| Free Cash Flow | — | — | 732.77M | 925.95M |